JP2025512098A5 - - Google Patents

Info

Publication number
JP2025512098A5
JP2025512098A5 JP2024560594A JP2024560594A JP2025512098A5 JP 2025512098 A5 JP2025512098 A5 JP 2025512098A5 JP 2024560594 A JP2024560594 A JP 2024560594A JP 2024560594 A JP2024560594 A JP 2024560594A JP 2025512098 A5 JP2025512098 A5 JP 2025512098A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
substituted
membered
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560594A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/053399 external-priority patent/WO2023199091A1/en
Publication of JP2025512098A publication Critical patent/JP2025512098A/ja
Publication of JP2025512098A5 publication Critical patent/JP2025512098A5/ja
Pending legal-status Critical Current

Links

JP2024560594A 2022-04-12 2022-04-12 複素環化合物 Pending JP2025512098A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2022/053399 WO2023199091A1 (en) 2022-04-12 2022-04-12 Heterocyclic compound

Publications (2)

Publication Number Publication Date
JP2025512098A JP2025512098A (ja) 2025-04-16
JP2025512098A5 true JP2025512098A5 (enExample) 2025-04-23

Family

ID=81749305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560594A Pending JP2025512098A (ja) 2022-04-12 2022-04-12 複素環化合物

Country Status (4)

Country Link
US (1) US20250250230A1 (enExample)
EP (1) EP4508027A1 (enExample)
JP (1) JP2025512098A (enExample)
WO (1) WO2023199091A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374610A1 (en) 1999-06-28 2001-01-04 Jordan J. N. Tang Catalytically active recombinant memapsin and methods of use thereof
WO2005058808A1 (en) * 2003-12-15 2005-06-30 Japan Tobacco Inc. N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
DK2195293T3 (da) * 2007-08-22 2014-02-03 Astrazeneca Ab Cyclopropylamidderivater
EP2694472B1 (en) 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
PL3411358T3 (pl) * 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
US11034700B2 (en) * 2017-03-08 2021-06-15 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
WO2018164191A1 (ja) * 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US20200207734A1 (en) 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP7413261B2 (ja) 2018-06-29 2024-01-15 武田薬品工業株式会社 複素環化合物およびその用途
US12077522B2 (en) 2018-06-29 2024-09-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
EP3896060B1 (en) 2018-12-12 2023-08-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
SG11202106791XA (en) 2019-01-31 2021-07-29 Takeda Pharmaceuticals Co Heterocyclic compound and use thereof
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
JP7172813B2 (ja) 2019-04-09 2022-11-16 中西金属工業株式会社 吊車
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
JP2022064180A (ja) * 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物

Similar Documents

Publication Publication Date Title
JP2025512098A5 (enExample)
JP2020510010A5 (enExample)
JP2023529354A5 (enExample)
RU2015136770A (ru) Хинолинамиды и хиназолинамиды в качестве модуляторов натриевых каналов
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
FI3743406T3 (fi) Tmem16a-modulaattoreita
JP2021512143A5 (enExample)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2007142336A (ru) Арилалкилзамещенные производные кислот и их применение
JP2016506963A5 (enExample)
RU2010107892A (ru) Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их
JP2020533352A5 (enExample)
JP2003506348A (ja) Ccr−3受容体のインヒビターとしての尿素誘導体
JP2021530513A5 (enExample)
JP2021102643A5 (enExample)
JP2020511536A5 (enExample)
JP2016516028A5 (enExample)
JP2024516826A5 (enExample)
JP2024507810A5 (enExample)
JP2023547241A5 (enExample)
JP2024517861A5 (enExample)
JP2020111571A5 (enExample)
JP2019529460A5 (enExample)
JP2023525359A5 (enExample)
JP2025508359A5 (enExample)